News from NLA
(Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - November 1, 2022 Category: Lipidology Source Type: research
Editorial Board
(Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - November 1, 2022 Category: Lipidology Source Type: research
Table of Contents
(Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - November 1, 2022 Category: Lipidology Source Type: research
Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic
On December 22, 2021, the United States FDA approved inclisiran, an siRNA targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and statin therapy for low-density lipoprotein cholesterol (LDL-C) reduction in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD).1 Inclisiran has demonstrated ∼50% time-averaged reduction in LDL-C and offers potential in promoting patient adherence as a twice-yearly long-acting injectable. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - October 31, 2022 Category: Lipidology Authors: Tommy T. Chiou, Kimberly Tomasi, Pam R. Taub, Michael J. Wilkinson Tags: Brief Communication Source Type: research
The Relationship of Alcohol Consumption and HDL Metabolism in the Multiethnic Dallas Heart Study
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death worldwide. It is generally regarded that there is an inverse relationship between high-density lipoprotein cholesterol (HDL-C) and ASCVD risk.1 However, therapeutic attempts to raise serum HDL-C did not decrease ASCVD risk, raising evidence against this hypothesis. A key anti-atherosclerotic property of HDL is the ability to promote reverse cholesterol transport, the movement of cholesterol from macrophages in the blood vessel walls to circulating HDL particles for excretion via the liver. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - October 28, 2022 Category: Lipidology Authors: Rohit R Badia, Roma V Pradhan, Colby R Ayers, Alvin Chandra, Anand Rohatgi Source Type: research
Effect of evolocumab on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia
Familial dysbetalipoproteinemia (FD), also known as ‘remnant removal disease’, is the second most common monogenic lipid disorder after heterozygous familial hypercholesterolemia (heFH), with an estimated prevalence of 1 in 850 to 1 in 3500 individuals.1 In clinical practice, FD is often not recognized and therefore underdiagnosed. FD is characte rized by the accumulation of cholesterol-enriched remnants of triglyceride-rich lipoproteins (TRLs). TRLs are atherogenic and causally related to cardiovascular disease (CVD). (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - October 28, 2022 Category: Lipidology Authors: Britt E Heidemann, Charlotte Koopal, Jeanine E Roeters van Lennep, Erik S Stroes, Niels P Riksen, Monique T Mulder, Leonie C van Vark – van der Zee, Dee M Blackhurst, A David Marais, Frank LJ Visseren Source Type: research
Lipoprotein(a) and inflammation- pathophysiological links and clinical implications for cardiovascular disease
Lipoprotein(a) [Lp(a)], a molecule firstly described in 1963 by Berg et al, has attracted intense research as an independent cardiovascular disease (CVD) risk factor and a novel therapeutic target1. Lp(a) consists of a low density lipoprotein (LDL)-like particle bound by a disulfide bond to apolipoprotein(a) which is the distinctive feature discriminating Lp(a) from the LDL moiety2. Several studies have observed higher Lp(a) levels in CVD patients and the causality of the association between high Lp(a) levels and CVD was confirmed in Mendelian randomization studies, which showed that the LPA gene and shorter apolipoprotein...
Source: Journal of Clinical Lipidology - October 19, 2022 Category: Lipidology Authors: Spyridon Simantiris, Alexios S. Antonopoulos, Charalampos Papastamos, Georgios Benetos, Nikolaos Koumallos, Konstantinos Tsioufis, Dimitris Tousoulis Tags: Review Article Source Type: research
A Stepwise Approach to Prescribing Novel Lipid-Lowering Medications
Ischemic heart disease remains the leading cause of death worldwide and dyslipidemia is a major modifiable risk factor for developing atherosclerotic cardiovascular disease (ASCVD)1. There is an enormous body of evidence from Mendelian and randomized controlled trials (RCTs) confirming that reducing low-density lipoprotein-cholesterol (LDL-C) correlates well with reducing ASCVD2. Statins are the standard of treatment and reduce LDL-C by 30 to 63 percent based on intensity3, and the addition of ezetimibe can augment this effect by about 14 percent4. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - October 18, 2022 Category: Lipidology Authors: Hessam Kakavand, Maryam Aghakouchakzadeh, Ali Shahi, Salim S. Virani, Dave L. Dixon, Benjamin W. Van Tassell, Azita H. Talasaz Tags: Review Article Source Type: research
Ethyl EPA and ethyl DHA cause similar and differential changes in plasma lipid concentrations and lipid metabolism in subjects with low-grade chronic inflammation
Elevated plasma concentrations of triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C) are established risk factors for cardiovascular disease (CVD),1, 2 the main cause of morbidity and mortality in the U.S.3 Mendelian randomization studies and clinical trials support a causative role of TG and LDL-C in the pathophysiology of CVD.4, 5 Elevations in TG and LDL-C concentrations are prevalent in the U.S. population, especially in older individuals with metabolic syndrome.6, 7 The characteristic plasma lipid abnormalities observed in metabolic syndrome are usually associated with alterations in enzymes mediating ...
Source: Journal of Clinical Lipidology - October 15, 2022 Category: Lipidology Authors: Jisun So, Bela F. Asztalos, Katalin Horvath, Stefania Lamon-Fava Source Type: research
Simulation of Lipid-Lowering Therapy (LLT) Intensification in Very High-Risk Patients with Atherosclerotic Cardiovascular Disease
In a previous study, we used a Monte Carlo simulation model to estimate the proportion of patients with atherosclerotic cardiovascular disease (ASCVD) who would require various lipid-lowering therapies (LLTs), and the proportion achieving low-density lipoprotein cholesterol (LDL-C) goals via a stepwise treatment intensification algorithm which maximized statins before adding ezetimibe and a proprotein convertase subtilisin/kexin type 9 (PCSK9 inhibitor).1 We found that, after treatment intensification, 99.3% of patients could achieve an LDL-C level of (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - October 13, 2022 Category: Lipidology Authors: Jing Gu, Robert J Sanchez, Ankita Chauhan, Sergio Fazio, Robert S Rosenson Tags: Brief Communication Source Type: research
Impact of Variants of Uncertain Significance of LDL receptor on Phenotypes of Familial Hypercholesterolemia
Familial hypercholesterolemia (FH) is caused by a pathogenic mutation in LDL receptor (LDLR) or its associated genes, including apolipoprotein B (APOB), proprotein convertase subtilisin/kexin type 9 (PCSK9), and LDLR adaptor protein 1 (LDLRAP1) 1. Genetic testing for this disorder is important because 1) this is one of the most common Mendelian diseases 2, 3, 2) identification of pathogenic variants leads not only to their diagnosis but also to their risk stratification 4, 5, and 3) early diagnosis and treatment will lead to their better prognosis 6-9. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - September 29, 2022 Category: Lipidology Authors: Hayato Tada, Nobuko Kojima, Kan Yamagami, Akihiro Nomura, Atsushi Nohara, Soichiro Usui, Kenji Sakata, Kenshi Hayashi, Noboru Fujino, Masayuki Takamura, Masa-aki Kawashiri Source Type: research
A mechanism-based operational definition and classification of hypercholesterolemia
Plasma concentration of atherogenic cholesterol is mainly determined by circulating levels of the cholesterol transported within the apoB-containing lipoproteins represented by low-density lipoproteins (LDL) but also small very low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL) and lipoprotein(a) [Lp(a)]1,2. These fractions of circulating cholesterol are recognized to be the causal factor for development of atherosclerotic cardiovascular disease (ASCVD)3. Therefore, the precise blood lipid measurements and the reduction of circulating levels of atherogenic lipoproteins are key procedures to reduce the...
Source: Journal of Clinical Lipidology - September 29, 2022 Category: Lipidology Authors: Fernando Civeira, Marcello Arca, Ana Cenarro, Robert A. Hegele Tags: Review Article Source Type: research
Guidance for the diagnosis and treatment of hypolipidemia disorders
abetalipoproteinemia (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - September 28, 2022 Category: Lipidology Authors: Cindy Bredefeld, M. Mahmood Hussain, Maurizio Averna, Dennis D. Black, Mitchell F. Brin, John R. Burnett, Sybil Charri ère, Charlotte Cuerq, Nicholas O. Davidson, Richard J. Deckelbaum, Ira J. Goldberg, Esther Granot, Robert A. Hegele, Shun Ishibashi, Wa Tags: Review Article Source Type: research
Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy
Lipodystrophy syndromes involve selective deficiency of adipose tissue and are categorized as generalized, characterized by near total lack of fat, or partial lipodystrophy, characterized by regional deficiency of fat in the lower extremities and preservation or even excess fat in the face, neck, and/or trunk.1 Partial lipodystrophy can be further classified as familial (most commonly caused by heterozygous mutations in LNMA and PPARG) or acquired (often associated with autoimmune conditions). The diagnosis of lipodystrophy is made clinically, with genetic studies performed to complement the clinical diagnosis. (Source: Jo...
Source: Journal of Clinical Lipidology - September 21, 2022 Category: Lipidology Authors: Marissa Lightbourne, Megan Startzell, Kimberley D. Bruce, Brianna Brite, Ranganath Muniyappa, Monica Skarulis, Robert Shamburek, Ahmed M. Gharib, Ronald Ouwerkerk, Mary Walter, Robert H. Eckel, Rebecca J. Brown Source Type: research
Assessment of Efficacy and Safety of Volanesorsen for Treatment of Metabolic Complications in Patients With Familial Partial Lipodystrophy: Results of the BROADEN Study
Familial partial lipodystrophy (FPLD) is a rare genetic disorder characterized by variable loss of subcutaneous adipose tissue from the peripheral depots and increased adipose tissue accumulation in other body regions such as the face, chin, neck, perineum, and intra-abdominal area.1-3 This adipocyte loss is associated with severe insulin resistance that can lead to diabetes mellitus, hypertriglyceridemia, and nonalcoholic steatohepatitis.1,2 Onset of loss of subcutaneous fat from the extremities typically occurs during prepuberty or puberty. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - September 21, 2022 Category: Lipidology Authors: Elif A. Oral, Abhimanyu Garg, Joseph Tami, Eric A. Huang, Louis St. L. O'Dea, Hartmut Schmidt, Anatoly Tiulpakov, Ann Mertens, Veronica J. Alexander, Lynnetta Watts, Eunju Hurh, Joseph L. Witztum, Richard S. Geary, Sotirios Tsimikas Source Type: research
